Login

Subscribe   My Account  

Login
Username:
Password:
Remember Me
Login securely
 
Important Updates for Investors

Carla Pasternak's Premiere Issue of High-Yield International Just Released
Income expert Carla Pasternak's debut issue of High-Yield International covers a Taiwanese manufacturer yielding 9.5%... a rare Mexican monopoly yielding 13.4%... and other top-performing investments yielding up to 19.0%.
 

Government's Biofuel Timetable Could Spell +15,900% Growth
+15,900% growth might seem far-fetched... but it's not. In fact, it is mandated by law. And I've identified the ONLY stock positioned to capture this growth.

The Silver Lining to a Falling Dollar
Despite the U.S. national debt, there is a silver lining for income investors. This massive spending, combined with movement out of U.S. Treasuries, is going to take its toll on the dollar, and international income investors could reap the rewards in the form of higher dividends.



ETF Spotlight -- Biotech HOLDR (BBH)

 

By Nathan Slaughter
Editor, The ETF Authority

Visit this link to learn more about this premium newsletter.
View our subscription options for The ETF Authority.

Published:  February 9, 2004

The Biotech HOLDR (BBH, $141.50) is an exchange-traded fund that consists of a basket of 18 Biotechnology firms. You could really call this the "Am-Genentech Fund," as Biotech giants Amgen (AMGN, $64.86) and Genentech (DNA, $96.52) account for nearly 60% of this HOLDR's value. So, when you invest in this fund, you truly need to have a technical view of these two securities and should certainly know when they are going to release earnings, announce major drug development decisions from the FDA, or are involved in important Biotech conferences. These kinds of events can lead to huge moves in Biotech stocks. It does not hurt to know if and when their competition is working on alternate drugs as well, although knowledge of the companies' charts and a background in their own events will give you the requisite information.

Note that I listed the Pharmaceutical HOLDR (PPH, $83.84) as a related issue in the table below. However, the correlation between PPH and BBH is fairly low, at about 58%. This makes sense. PPH mostly holds developed companies that have steady returns. By contrast, most biotech firms are highly specialized and are still in the developmental stage. They are very speculative. While pharmaceutical firms in PPH are sometimes considered defensive in nature, most stocks in BBH would not even come close to falling into that category. From high to low, BBH tumbled -71% during the bear market. Although the fund then bottomed well before the broader market (July 2002 compared with October 2002), I would not categorize BBH as defensive.

A quick note about HOLDRS...
HOLDRS, which are managed by brokerage giant Merrill Lynch, are a bit different from traditional ETFs in the way they trade and in their expense ratios. For example, you cannot buy or sell fewer than 100 shares of a HOLDR in any transaction. Instead, these unique instruments can only be traded in 100-share round lots. In addition, unlike most other types of funds, which track broad-based indices that contain hundreds (or some cases even thousands) of stocks, most HOLDRS consist of just a handful of stocks and are designed to track a particular industry group. Because they only track a few companies, HOLDRS are very inexpensive to manage. However, because they aren't highly diversified, they also tend to be much more volatile than the average ETF. HOLDRS also directly pass through any distributions the underlying securities make. This may lead to tax consequences different than what you would expect from an ordinary ETF. Note that because the fund's components never change, corporate restructurings and changes could ultimately result in a HOLDR no longer being representative of its original sector design. After purchasing a HOLDR, you will receive annual and quarterly reports from each individual company held by the fund.

Biotech HOLDR (BBH)
Type: Sector
Similar funds: Nasdaq Biotech (IBB)
Pharmaceutical HOLDR (PPH)
Options?: Yes, illiquid
Performance Data
52-week High: $144.09 2/3/2004 Annualized return since:
52-week Low: $84.84 2/13/2003 One-year 63.21%
2003 Return: 60.02% Three-year -1.70%
Five-year N/A
Dividends: $0.00   past 12-mos Life of fund* 7.18%
Expense Ratio: $0.08 per share per year * - Started trading 11/23/99
Correlation Data* (1/02/02-1/31/04) Holdings* (as of 2/5/2004)
Dow Jones Industrials 62.8% Genentech (DNA) 30.12%
S&P 500 68.4% Amgen (AMGN) 29.69%
Nasdaq Composite 70.8% Biogen Idec (BIIB) 8.11%
Nasdaq-100 70.8% Gilead (GILD) 6.39%
Chiron (CHIR) 5.94%
IBB 92.9% Genzyme (GENZ) 5.49%
PPH 58.0% Applera Corp. (ABI) 2.94%
MedImmune (MEDI) 2.60%
Millennium Pharm. (MLNM) 1.52%
Shire Pharm. (SHPGY) 1.45%
* Percent top ten are of total 94.25%
Average Daily Volume Average Daily Price Range
Jan-04 795,350 Jan-04 1.7%
2003 1,060,516 2003 2.3%
2002 1,468,535 2002 3.8%
* - Correlation measures how closely the two items track each other * Includes prior day's close (true range)

HOW TO MAKE MONEY IN BBH THIS YEAR
Although I still see a chance at one more new high in the broad stock market, BBH may very well have already peaked. This fund has more than doubled in the past 18 months and is now due for a large fall, so long-term traders should hold short positions here. My minimum downside target is near $114, but the fund could even fall as low as $105, and perhaps even $96, sometime within the next year. I would stay short as long as the fund does not rally past $162.

 

FREE StreetAuthority Newsletters


Register for FREE to Investor Update

In each issue of Investor Update, you'll receive actionable investment advice from StreetAuthority's best minds. Let Investor Update bring you the top ways to profit in today's market.

Register for FREE to Dividend Opportunities

Join Carla Pasternak each week on her quest for high yields -- no matter where on the globe they hide. In every issue, Carla is on the hunt for yields of 8%... 10%... even 12% or more!

Register for FREE to Trade of the Week

Mike Turner brings you his single best trading idea each and every week. Mike's proprietary trading system has earned him returns as high as +3,205% on individual stocks and +54% in a week!

 
McAfee Secure sites help keep you safe from identity theft, credit card fraud, spyware, spam, viruses and online scams
  We hate spam as much as you do. Read our privacy policy.
 



6 Free Months of Bernie Schaeffer's Option Advisor
Learn the secrets of successful options trading from top trader, Bernie Schaeffer. Start your free 6-month subscription to The Option Advisor newsletter now and get free online access to Bernie's Crash Course in Top Gun Trading Techniques.

3 Penny Stocks Poised to Soar 300%
By the time Wall Street notices the 3 picks revealed in this report, you could be sitting on a fortune.  Click here to get immediate access to an exclusive Free report -- "3 Underground Penny Stocks Poised to Soar."

 

Investor's Business Daily (IBD)
Get 10 Free Issues of Investor's Business Daily (IBD) – Plus 2 Free Weeks of Investors.com

52 Wins in 52 Weeks - 365 Days Without A Loss
Success Trading Group scored 52 wins in 52 weeks! Get their weekend newsletters free and register for Success Trading Group's next stock picks free for 30 days!

 

Investing Doesn't Get Any Easier Than This

Stock picker Amy Calistri's strategy is as simple as investing gets -- just one idea a month designed to make money in today's market. Invest this way and you don't have to worry about oil prices, automaker bailouts, or what the Fed is up to -- because every "bad" economic development actually helps some investment or another.Your investing life can get a lot simpler -- starting today.
Go here to learn about Amy's simple investing strategy.
 


StreetAuthority's Lifetime Wealth Alliance


High-Yield Investing


Market Advisor


Stock of the Month


Government-Driven Investing


High-Yield International


The ETF Authority


Half-Priced Stocks


Dividend Opportunities


Investor Update







Google
 
Web StreetAuthority.com


About StreetAuthority    Email Newsletters    My Subscriptions    Manage My Account    Job Opportunities
Contact Us    Affiliates    Disclaimer    Help    Site Map

© Copyright 2001-2009 StreetAuthority, LLC  All Rights Reserved